PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
07 03 2019
Historique:
entrez: 10 3 2019
pubmed: 10 3 2019
medline: 24 3 2020
Statut: epublish

Résumé

Women in regions with high HIV prevalence are at high risk of HIV acquisition during pregnancy and postpartum, and acute maternal HIV contributes a substantial proportion of infant HIV infections. Pre-exposure prophylaxis (PrEP) could prevent HIV during pregnancy/postpartum; however, identifying women who would most benefit from PrEP in this period is challenging. Women may not perceive risk, may not know partner HIV status and partners may have external partners during this period. PrEP offer in pregnancy could be universal or risk guided. The PrEP Implementation for Mothers in Antenatal Care (PrIMA) study is a cluster randomised trial that aims to determine the best model for PrEP implementation in pregnancy, among women attending public sector maternal child health clinics in Western Kenya (HIV prevalence >25%). Twenty clinics are randomised to either universal PrEP offer following standardised counselling ('Universal arm' 10 clinics) or risk screening with partner self-test option ('Targeted arm' 10 clinics). Four thousand women will be enrolled and followed through 9-month postpartum. The primary analysis will be intention to treat. Outcomes reflect the balance between HIV preventive effectiveness and avoiding unnecessary PrEP exposure to women at low risk and include: maternal HIV incidence, PrEP uptake, PrEP adherence, PrEP duration, 'appropriate' PrEP use (among women with objective evidence of potential risk), infant birth outcomes, infant growth and partner self-testing uptake. To better understand the feasibility and acceptability of the provision of PrEP in these settings, qualitative interviews and cost-effectiveness analyses will be conducted. The protocol was approved by the institutional review boards at Kenyatta National Hospital and the University of Washington. An external advisory panel monitors adverse and social harm events. Results will be disseminated through peer-reviewed journals, presentations at local and international conferences to national and global policy makers, community and participants. NCT03070600.

Identifiants

pubmed: 30850409
pii: bmjopen-2018-025122
doi: 10.1136/bmjopen-2018-025122
pmc: PMC6430021
doi:

Substances chimiques

Anti-HIV Agents 0

Banques de données

ClinicalTrials.gov
['NCT03070600']

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e025122

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI125498
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Trials. 2012 Aug 01;13:120
pubmed: 22853820
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
AIDS. 2017 Jan 14;31(2):213-232
pubmed: 27831952
Lancet. 1992 Sep 5;340(8819):585-8
pubmed: 1355163
Soc Sci Med. 2017 Jan;172:115-123
pubmed: 27866750
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
Clin Infect Dis. 2013 Dec;57(12):1773-81
pubmed: 24046310
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
Fam Pract. 1996 Dec;13(6):522-5
pubmed: 9023528
PLoS Med. 2016 Sep 27;13(9):e1002132
pubmed: 27676257
AIDS Patient Care STDS. 2018 May;32(5):202-207
pubmed: 29672136
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038282
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
Acta Paediatr Suppl. 2006 Apr;450:76-85
pubmed: 16817681
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
J Infect Dis. 2009 Sep 1;200(5):667-9
pubmed: 19627246
AIDS. 2015 Sep 24;29(15):2025-33
pubmed: 26352880
PLoS One. 2015 Apr 17;10(4):e0122433
pubmed: 25886375
AIDS Behav. 2017 May;21(5):1376-1382
pubmed: 28238119
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090

Auteurs

Julia C Dettinger (JC)

Department of Global Health, University of Washington, Seattle, Washington, USA.

John Kinuthia (J)

Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya.

Jillian Pintye (J)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Nancy Mwongeli (N)

Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya.

Laurén Gómez (L)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Barbra A Richardson (BA)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Biostatistics, University of Washington, Seattle, Washington, USA.

Ruanne Barnabas (R)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.

Anjuli D Wagner (AD)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Gabrielle O'Malley (G)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Jared M Baeten (JM)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.

Grace John-Stewart (G)

Department of Global Health, University of Washington, Seattle, Washington, USA.
Department of Medicine, University of Washington, Seattle, Washington, USA.
Department of Epidemiology, University of Washington, Seattle, Washington, USA.
Department of Pediatrics, University of Washington, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH